An NLRC4 mutation in patients with MAS was reported to increase the production of IL-18, and neutralization of IFN-γ reversed the clinical and laboratory characteristics of MAS in a mouse model (8, 10, 56), expanding the possibilities of uncovering more cytokine blockers. This evidence concerns the gene NLRC4 and macrophage activation syndrome.